Intellia Therapeutics, Inc. NTLA
Set alert
11.66 USD -0.81 -6.50%
At close
11.70 +0.04 +0.34%
Pre-market · Nov 3, 8:08 AM ET
11.59 Day range 12.61
7.95 52-week range 18.48
- YTD
- +29.70%
- 1 year
- -10.79%
- Open
- 12.60
- Prev close
- 12.47
- Mkt cap
- 1.63B
- Vol
- 3.88M
- Avg vol
- 4.39M
- EPS
- -3.35
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 11.59
- High
- 12.61
- Forward P/E
- -4.55
- Beta
- 1.82
- Short ratio
- 7.63
- Inst. own
- 100.56%
- Dividend
- 0.00
- Ex-div date
- Earnings
- Nov 5, 2026
- 50-d avg
- 12.23
- 200-d avg
- 13.08
- 1y target
- 23.11
MAX chart
Events in this range
- Aug 7, 2025Earnings: -0.99; estimate -1.03; surprise 3.88%
- Nov 6, 2025Earnings: -0.92; estimate -1.02; surprise 9.8%
- Aug 6, 2026Earnings: -0.8; estimate -0.79927; surprise -0.09%
- Aug 7, 2026Rating: Evercore ISI Group · In-Line → Outperform
- Oct 6, 2026Rating: Barclays · — → Underweight
- Nov 5, 2026Earnings: —; estimate -0.79699; surprise —%
Signals (32)
| Name | Date | Ago |
|---|---|---|
| SMA: Bearish | Sep 1, 2026 | 2 months ago |
| SMA: Bullish | Aug 1, 2026 | 3 months ago |
| SMA: Bearish | Jul 1, 2026 | 4 months ago |
| SMA: Bearish | Jul 1, 2026 | 4 months ago |
| SMA: Bullish | Jun 1, 2026 | 5 months ago |
| SMA: Bullish | Jan 1, 2026 | 10 months ago |
| SMA: Bearish | Nov 1, 2025 | 1 year ago |
| SMA: Bullish | Jul 1, 2025 | 1 year ago |
| MACD: Buy Signal | Jun 1, 2025 | 1 year ago |
| MACD: Sell Signal | Oct 1, 2024 | 2 years ago |
| SMA: Bearish | Aug 1, 2024 | 2 years ago |
| SMA: Bullish | Jul 1, 2024 | 2 years ago |
| MACD: Buy Signal | Jul 1, 2024 | 2 years ago |
| SMA: Bearish | Aug 1, 2023 | 3 years ago |
| SMA: Bullish | Jul 1, 2023 | 3 years ago |
| SMA: Bearish | Apr 1, 2022 | 4 years ago |
| MACD: Sell Signal | Feb 1, 2022 | 4 years ago |
| SMA: Bearish | Dec 1, 2021 | 4 years ago |
| RSI: Overbought | Nov 1, 2020 | 6 years ago |
| SMA: Bullish | Aug 1, 2020 | 6 years ago |
Newest 20 of 32.
Analyst view
Consensus: none
Price target (mean) 23.11 +98.2% upside
Now 11.66
- Target (low)
- 8.00
- Target (mean)
- 23.11
- Target (high)
- 61.00
Ratings (0m) 20 10 buy · 6 hold · 4 sell
- Strong buy1
- Buy9
- Hold6
- Sell2
- Strong sell2
Recommendation trend
- This month 20
- 1 month ago 19
- 2 months ago 19
Earnings and revenue estimates
Consensus for the coming quarters and fiscal years
| Period | EPS estimate | Low – high | Year ago | EPS growth | Revenue estimate | Revenue growth | Analysts |
|---|---|---|---|---|---|---|---|
| Current quarter | -0.78559 | -0.89 – -0.71 | -0.92 | +14.6% | 9.77M | -29.1% | 16 |
| Next quarter | -0.75096 | -0.91 – -0.41 | -0.83 | +9.5% | 17.09M | -25.8% | 16 |
| Current year | -3.14 | -3.41 – -2.83 | -3.81 | +17.5% | 51.88M | -23.3% | 17 |
| Next year | -2.56 | -3.62 – 0.97 | -3.14 | +18.4% | 126.26M | +143.4% | 17 |
Upgrades and downgrades
The latest rating changes
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Oct 6, 2026 | Barclays | Initiated | — | Underweight |
| Sep 9, 2026 | Citizens | Reiterated | Market Outperform | Market Outperform |
| Sep 9, 2026 | Wedbush | Maintained | Neutral | Neutral |
| Sep 9, 2026 | HC Wainwright & Co. | Reiterated | Buy | Buy |
| Aug 25, 2026 | Citizens | Reiterated | Market Outperform | Market Outperform |
| Aug 7, 2026 | Evercore ISI Group | Upgrade | In-Line | Outperform |
| Jul 16, 2026 | Wolfe Research | Downgrade | Peer Perform | Underperform |
| Jul 10, 2026 | Wedbush | Maintained | Neutral | Neutral |
| Jun 16, 2026 | Canaccord Genuity | Maintained | Buy | Buy |
| Jun 15, 2026 | Citizens | Reiterated | Market Outperform | Market Outperform |
| Jun 15, 2026 | Wedbush | Reiterated | Neutral | Neutral |
| Jun 15, 2026 | HC Wainwright & Co. | Reiterated | Buy | Buy |
| May 13, 2026 | Bernstein | Maintained | Market Perform | Market Perform |
| May 13, 2026 | HC Wainwright & Co. | Maintained | Buy | Buy |
| May 12, 2026 | Canaccord Genuity | Maintained | Buy | Buy |
| May 12, 2026 | Wedbush | Reiterated | Neutral | Neutral |
| Apr 28, 2026 | Canaccord Genuity | Maintained | Buy | Buy |
| Apr 28, 2026 | Goldman Sachs | Maintained | Sell | Sell |
| Apr 28, 2026 | Morgan Stanley | Maintained | Equal-Weight | Equal-Weight |
| Apr 28, 2026 | Citizens | Maintained | Market Outperform | Market Outperform |
| Apr 27, 2026 | Chardan Capital | Maintained | Buy | Buy |
| Apr 27, 2026 | Baird | Maintained | Neutral | Neutral |
| Mar 4, 2026 | Jones Trading | Upgrade | Hold | Buy |
| Mar 3, 2026 | Canaccord Genuity | Maintained | Buy | Buy |
| Mar 3, 2026 | Leerink Partners | Maintained | Outperform | Outperform |
| Mar 3, 2026 | RBC Capital | Maintained | Sector Perform | Sector Perform |
| Mar 3, 2026 | Wells Fargo | Maintained | Equal-Weight | Equal-Weight |
| Mar 3, 2026 | Citizens | Maintained | Market Outperform | Market Outperform |
| Mar 3, 2026 | HC Wainwright & Co. | Maintained | Buy | Buy |
| Mar 2, 2026 | Chardan Capital | Maintained | Buy | Buy |